Sage Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
Sage Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 29.1% en 31.2% per jaar. De winst per aandeel zal naar verwachting groeien met 31.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -91.5% zijn.
Belangrijke informatie
29.1%
Groei van de winst
31.7%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 31.2% |
Toekomstig rendement op eigen vermogen | -91.5% |
Dekking van analisten | Good |
Laatst bijgewerkt | 30 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Oct 07Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
Jul 25Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 155 | -234 | -82 | -133 | 18 |
12/31/2025 | 92 | -286 | -260 | -269 | 21 |
12/31/2024 | 43 | -394 | -269 | -269 | 15 |
9/30/2024 | 106 | -338 | -320 | -320 | N/A |
6/30/2024 | 97 | -446 | -374 | -374 | N/A |
3/31/2024 | 91 | -503 | -425 | -425 | N/A |
12/31/2023 | 86 | -541 | -541 | -541 | N/A |
9/30/2023 | 11 | -656 | -549 | -548 | N/A |
6/30/2023 | 10 | -592 | -532 | -531 | N/A |
3/31/2023 | 9 | -558 | -507 | -506 | N/A |
12/31/2022 | 8 | -533 | -461 | -460 | N/A |
9/30/2022 | 6 | -510 | -432 | -431 | N/A |
6/30/2022 | 6 | -503 | -381 | -381 | N/A |
3/31/2022 | 6 | -484 | -377 | -377 | N/A |
12/31/2021 | 6 | -458 | -379 | -378 | N/A |
9/30/2021 | 1,114 | 642 | 730 | 730 | N/A |
6/30/2021 | 1,114 | 666 | 708 | 708 | N/A |
3/31/2021 | 1,113 | 637 | 692 | 692 | N/A |
12/31/2020 | 1,114 | 606 | 664 | 664 | N/A |
9/30/2020 | 7 | -537 | -464 | -463 | N/A |
6/30/2020 | 9 | -612 | -504 | -501 | N/A |
3/31/2020 | 9 | -644 | -520 | -515 | N/A |
12/31/2019 | 7 | -680 | -534 | -529 | N/A |
9/30/2019 | 5 | -670 | -520 | -514 | N/A |
6/30/2019 | 2 | -613 | -470 | -465 | N/A |
3/31/2019 | 91 | -462 | -335 | -332 | N/A |
12/31/2018 | 90 | -373 | -264 | -261 | N/A |
9/30/2018 | 90 | -284 | -221 | -218 | N/A |
6/30/2018 | 90 | -235 | N/A | -184 | N/A |
3/31/2018 | N/A | -288 | N/A | -243 | N/A |
12/31/2017 | N/A | -270 | N/A | -219 | N/A |
9/30/2017 | N/A | -257 | N/A | -194 | N/A |
6/30/2017 | N/A | -221 | N/A | -179 | N/A |
3/31/2017 | N/A | -185 | N/A | -146 | N/A |
12/31/2016 | N/A | -159 | N/A | -119 | N/A |
9/30/2016 | N/A | -132 | N/A | -103 | N/A |
6/30/2016 | N/A | -118 | N/A | -92 | N/A |
3/31/2016 | N/A | -108 | N/A | -84 | N/A |
12/31/2015 | N/A | -94 | N/A | -71 | N/A |
9/30/2015 | N/A | -78 | N/A | -61 | N/A |
6/30/2015 | N/A | -64 | N/A | -49 | N/A |
3/31/2015 | N/A | -47 | N/A | -36 | N/A |
12/31/2014 | N/A | -36 | N/A | -27 | N/A |
9/30/2014 | N/A | -29 | N/A | -23 | N/A |
6/30/2014 | N/A | -24 | N/A | -21 | N/A |
3/31/2014 | N/A | -21 | N/A | -20 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat SAGE de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van SAGE ( 31.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van SAGE ( 31.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat SAGE binnen 3 jaar verliesgevend zal zijn.